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Amlodipine Reduces AngII-Induced Aortic Aneurysms
and Atherosclerosis in Hypercholesterolemic Mice
Xiaofeng Chen1, Debra L. Rateri1, Deborah A. Howatt1, Anju Balakrishnan1, Jessica J. Moorleghen1,
Andrew J. Morris1, Richard Charnigo2, Lisa A. Cassis3, Alan Daugherty1*
1 Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America, 2 Department of Biostatistics, University of
Kentucky, Lexington, Kentucky, United States of America, 3 Department of Molecular and Biochemical Pharmacology, University of Kentucky, Lexington,
Kentucky, United States of America

Abstract
Background: The purpose of this study was to determine effects of amlodipine, a dihydropyridine calcium channel
blocker, on development of angiotensin II (AngII)-induced vascular pathologies.
Methods and Results: Male LDL receptor -/- mice were infused with vehicle, amlodipine (5 mg/kg/d), AngII (1,000
ng/kg/min), or AngII + amlodipine for 4 weeks through osmotic pumps (n=10/group). Mice were fed a saturated fatenriched diet for 1 week prior to pump implantation and during 4 weeks of infusion. Infusion of amlodipine resulted in
plasma concentrations of 32 ± 2 ng/ml and 27 ± 2 ng/ml for mice in saline + amlodipine and AngII + amlodipine
groups, respectively. This infusion rate of amlodipine did not affect AngII-induced increases in systolic blood
pressure. Three of 10 (30%) mice infused with AngII died of aortic rupture, while aortic rupture did not occur in mice
co-infused with AngII + amlodipine. Suprarenal aortic width and intimal area of ascending aortas were measured to
define aortic aneurysms. In the absence of AngII infusion, amlodipine did not change suprarenal aortic width and
ascending aortic area. Infusion of AngII led to profound increases of suprarenal aortic width (saline + vehicle versus
AngII + vehicle: 0.86 ± 0.02 versus 1.72 ± 0.26 mm; P=0.0006), whereas co-infusion of AngII and amlodipine
diminished abdominal dilation (1.02 ± 0.14 mm; P=0.003). As expected, AngII infusion increased mean intimal area
of ascending aortas (saline + vehicle versus AngII + vehicle: 8.5 ± 0.3 versus 12.5 ± 1.1 mm2; P=0.001), while coinfusion of AngII and amlodipine ablated dilation of the ascending aorta (8.6 ± 0.2 mm2; P=0.03). Co-administration of
amlodipine also significantly attenuated AngII-induced atherosclerosis in the thoracic region as quantified by percent
lesion area (AngII + vehicle versus AngII + amlodipine: 5.8 ± 2.1 % versus 0.3 ± 0.1%; P=0.05).
Conclusions: Amlodipine inhibited AngII-induced aortic aneurysms in both the abdominal and ascending regions,
and atherosclerosis in hypercholesterolemic mice.
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Introduction

it has been noted that AngII infusion also promotes pronounced
dilation of the thoracic aorta, which is restricted to the
ascending region [12,13]. In addition to promoting formation of
aortic aneurysms, many studies have reported that chronic
subcutaneous infusion of AngII into mice augments
development of atherosclerosis in both apoE -/- and LDL
receptor -/- mice [8,9,14].
Since AngII infusion into hypercholesterolemic mice
promotes diverse aortic pathologies, this model permits
simultaneous determination of effects of an intervention on
abdominal and thoracic aortic aneurysms as well as

Aortic aneurysmal and atherosclerotic diseases may occur
coincidently in humans [1-5]. Excessive stimulation of the renin
angiotensin system (RAS) has been implicated in many human
cardiovascular diseases, including aortic aneurysms and
atherosclerosis [6,7]. There are substantial experimental data
that excessive RAS activation also promotes these diseases in
animal models. AngII infusion into LDL receptor -/-, apoE -/- or
normolipidemic mice induces development of aneurysms in the
suprarenal region of the abdominal aorta [8-11]. More recently,
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atherosclerosis. Several studies have demonstrated that
interventions can have differential effects on abdominal aortic
aneurysms
and
atherosclerosis.
These
include
pharmacological interventions with doxycycline, bosentan, and
pioglitazone [15-17], and surgical interventions such as
orchidectomy [18]. Genetic manipulations have also provided
divergent effects including whole body genetic deletion of
interferon-gamma, CXCL10, receptor-associated protein, or
Rag-1 [19-21], and cell-specific deletion of PPAR gamma or
AT1a receptors [17,22]. In contrast, several interventions have
similar effects on these pathologies including pharmacological
inhibition or whole body genetic deficiency of AT1a receptor
[23,24], an AT2 receptor antagonist [23] and whole body
deficiency of CCR2 [12]. Whole body deficiency of AT1a
receptor or CCR2 also decreased AngII-induced thoracic aortic
aneurysms [12,22]. Findings from these studies implicate that
the aortic pathologies in aneurysms and atherosclerosis may
be attributed to a combination of common and distinctive
mechanisms.
Anti-hypertensive drugs, including calcium channel blockers,
are commonly prescribed for hypertensive patients who
frequently also have aortic aneurysmal or atherosclerotic
diseases. Although one study indicates that this class of drugs
may have detrimental effects on abdominal aortic aneurysms in
humans [25], calcium channel blockade has been shown to
decrease atherosclerosis in humans [25-30]. However, this has
not been determined in prospective studies. The purpose of
this study was to determine effects of a commonly used
calcium channel blocker, amlodipine, on aortic pathologies in a
mouse model that develops aortic aneurysms and
atherosclerosis simultaneously.

expiration. Systolic blood pressure was measured by a tail cuff
based technique using Coda 8 machines (Kent Scientific,
Torrington, CT, USA) as described previously [31].

Diet and Drug Administration
To induce hypercholesterolemia, mice were fed a diet
enriched in saturated fat (milk fat 21% wt/wt) and 0.2% wt/wt
cholesterol (Diet # TD.88137; Harlan Teklad) 1 week prior to
osmotic mini-pump implantation and throughout the 4 weeks of
infusions.
Four groups (n=10 per group) of mice were infused with: 1.
saline + vehicle [50% dimethyl sulfoxide (DMSO)]; 2. saline +
amlodipine (5 mg/kg/day); 3. AngII (1,000 ng/kg/min) + vehicle
(50% DMSO); and 4. AngII + amlodipine. For osmotic pump
preparation (Durect Corporation; Cupertino, CA, USA), AngII
(1,000 ng/kg/min; Cat # H-1705; Bachem; Torrance, CA, USA)
was dissolved in saline. AngII and saline were infused using
Alzet model 1004. Amlodipine besylate (5 mg/kg/day; Cat #
A5605; Sigma-Aldrich; St. Louis, MO, USA) was dissolved in
50% DMSO. Amlodipine and vehicle (50% DMSO) were
infused using Alzet model 2004. After anesthesia with
ketamine/xylazine (90 and 10 mg/kg body weight, respectively),
a Model 1004 pump and a Model 2004 pump were implanted
subcutaneously into the flanks of each mouse [9]. A topical
analgesic, LMX4 (Ferndale Laboratories; Ferndale, MI, USA),
was used to provide relief from pain associated with surgery.

Plasma Measurements
Plasma cholesterol concentrations were measured using a
commercially available enzymatic kit (Cat # Cholesterol E
439-17501; Wako Chemicals; Richmond, VA, USA) as
described previously [32]. Plasma lipoprotein fractions were
resolved by size exclusion chromatography and cholesterol
concentrations were measured using the cholesterol enzymatic
kit as described previously [32].
Plasma amlodipine concentrations were measured by HPLC
electrospray ionization tandem mass spectrometry using
adaptation of a previously reported method [33]. Briefly,
individual plasma samples (50 μl) were extracted with ethyl
ether: dichloromethane (70:30). After centrifugation, the
supernatant was evaporated to dryness. Dried samples were
reconstituted in a mixture of ammonium formate/ methanol/
acetonitrile (30:50:20; 50 µl). Samples (10 μl) were analyzed
using a Shimadzu automated HPLC system with an Agilent
Eclipse XDB C18 column (Agilent; Santa Clara, CA, USA)
coupled with an AB Sciex 4000-Qtrap hybrid linear ion trap
triple quadrupole mass spectrometer (AB Sciex; Framingham,
MA, USA) that was operated in multiple reaction monitoring
mode. Tizanidine (Cat # T6950; Sigma Aldrich) was used as an
internal standard. Quantitation was accomplished by reference
to an offline calibration generated using amlodipine that was
independently quantitated by accurate mass measurements.
Plasma renin concentrations were measured as described
previously [34]. Briefly, individual plasma samples (8 μl)
harvested with EDTA (1.8 mg/ml) were incubated with an
excess of rat angiotensinogen at 37 °C for 30 minutes. The
generated AngI was quantified by radioimmunoassay using a

Materials and Methods
Ethics Statement
Recommendations from the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health) were
followed. All procedures were approved by the University of
Kentucky Institutional Animal Care and Use Committee
(Protocol # 2006-0009). Mice were examined daily for signs of
distress, dehydration, lack of weight gain, or bilateral hind leg
paralysis. No adverse effects were noted during this study.
Mice were terminated by overdose of a ketamine/xylazine
mixture.

Mice
Male low-density lipoprotein (LDL) receptor -/- mice (stock #
002207; > N10 background into the C57BL/6 background) were
purchased from the Jackson Laboratory (Bar Harbor, ME,
USA). Mice were housed in individually ventilated cages with
negative air pressure (Allentown Inc; Allentown, NJ, USA).
Filtered drinking water by reverse osmosis system was
provided ad libitum. Normal mouse diet (Global 18% protein
rodent diet; Diet # 2918; Harlan Teklad; Madison, WI, USA)
was fed. Light and dark cycle of the room was 14 hours of light
and 10 hours of dark. Ambient temperature ranged from 20 to
23°C and humidity was 50-60%. Necropsy was performed on
mice that died during AngII infusions within 12 hours of
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Figure 1. Plasma concentrations of amlodipine. Plasma concentrations of amlodipine were measured at the end of study.
Circles and triangles represent individual mice, diamonds are means of groups, and error bars are SEMs. * denotes P<0.0001
comparing amlodipine groups with saline + vehicle and AngII + vehicle groups by two way ANOVA.
doi: 10.1371/journal.pone.0081743.g001

Statistical Analyses

commercially available kit (Cat # 1553; DiaSorin; Stillwater,
MN, USA).

Data for continuous variables are summarized as means ±
standard error of means (SEM). Version 9.2 of SAS (SAS
Institute, Cary NC) was used for data analysis (SAS Institute
Inc.; Cary, NC, USA). Effects of AngII and amlodipine were
assessed by two-way analysis of variance (ANOVA) if
normality and equal variance assumptions were satisfied (or if
violations of these assumptions could be addressed by
transforming the data or reweighting the observations) and
were assessed posthoc by nonparametric Kruskal-Wallis test
otherwise. P≤0.05 was considered significantly different.

Quantification of Aortic Aneurysms and
Atherosclerosis
Aortas were dissected from the root to iliac bifurcation and
placed in 10% neutrally buffered formalin overnight. After
removal of adventitia, aortas were pinned and photographed.
Maximal ex vivo diameters of suprarenal aortas were
measured with ImagePro Plus software (Media Cybernetics;
Rockville, MD, USA) to quantitate AAAs [11,35]. Subsequently,
aortas were cut open longitudinally, secured with pins, and
photographed. To determine formation of thoracic aortic
aneurysms, dilation of ascending aortas was quantified by
measurement of intimal area of the ascending aortic region
[12]. Atherosclerosis was quantified on the intimal surface of
the aorta by an en face technique as described previously
[36,37].

Results
Characteristics of Study Mice
Amlodipine was infused subcutaneously through osmotic
pumps to maintain a constant plasma concentration throughout
the study. Plasma concentrations of amlodipine were not
significantly different between the groups that were co-infused
with either saline or AngII (32 ± 2 ng/ml and 27 ± 2 ng/ml,
respectively), while the drug was not detectable in saline +
vehicle or AngII + vehicle infused mice (Figure 1). Amlodipine
administration had no effect on body weight, plasma
cholesterol concentrations, and plasma lipoprotein-cholesterol
distributions in mice infused with either saline or AngII (Table
1). Amlodipine also had no significant effect on systolic blood
pressure in mice infused with AngII (150 ± 3 versus 148 ± 4
mmHg for AngII + vehicle versus AngII + amlodipine-infused
mice, respectively). AngII infusion significantly decreased
plasma renin concentration (P=0.005); however, addition of
amlodipine significantly increased plasma renin concentration
(P<0.0001; Table 1).

Histological and Immunohistochemical Staining
Aortic tissues were fixed with 4% paraformaldehyde, and
then sectioned on a cryostat at a thickness of 10 µm. Sections
were histologically stained using Verhoeff’s hematoxylin to
visualize the integrity of elastin. Immunohistochemical staining
was performed as described previously [38]. Smooth muscle
cells were detected using smooth muscle α-actin antibody (2
μg/ml; Abcam, cat# ab5694) and macrophages using an CD68
antibody (5 μg/ml; Serotec, cat# MCA1957GA). Positively
reactive areas were visualized via application of an ABC kit
(Vector) and subsequent detection with AEC chromogen
(Vector). Images were captured using a Nikon Eclipse E600
scope and a Nikon DXM1200F digital camera.

PLOS ONE | www.plosone.org

3

November 2013 | Volume 8 | Issue 11 | e81743

Amlodipine Attenuates Aortic Aneurysms

Figure 2. Survival curve for study mice. The survival curve for the four groups of mice during the infusion interval. Mice infused
with AngII + vehicle had 3 deaths (occurred on days 3, 4, and 8) due to aortic rupture, while no deaths occurred in the other groups.
doi: 10.1371/journal.pone.0081743.g002

whether any pathological changes were discernible, aortic
tissues were sectioned and immunohistochemically and
histologically stained. As the example shown in Figure 4,
suprarenal aortas from amlodipine infused mice were grossly
normal with consistent smooth muscle α-actin immunostaining,
intact elastin fibers in the media, and no accumulation of
macrophages.
En face measurement of intimal surface area of the
ascending aorta was used as an index to determine ascending
aortic dilation [12]. Administration of amlodipine had no effect
on ascending aortic area in saline-infused mice. AngII infusion
significantly increased mean intimal area of ascending aortas
(saline + vehicle versus AngII + vehicle: 8.5 ± 0.3 versus 12.5 ±
1.1 mm2; P=0.001). Co-infusion of AngII with amlodipine
ablated AngII-induced ascending aortic dilation (8.6 ± 0.2 mm2;
P=0.03; Figure 5). As with the suprarenal aorta, infusion of
amlodipine led to preservation of a normal histological
appearance of the ascending aorta (Figure 4).

Table 1. Characteristics of study mice.

Infusions

Saline

AngII

Vehicle

Amlodipine Vehicle

Amlodipine

n

10

10

7*

10

Body weight (g)

28.0 ± 0.5

27.6 ± 0.5

26.9 ± 0.6

26.9 ± 0.5

Plasma cholesterol (mg/dl)

1038 ± 41

949 ± 41

1168 ± 49

1119 ± 41

Plasma renin (ng/ml/30 min)

3.0 ± 0.3

8.5 ± 1.3†

1.1 ± 0.1#

5.2 ± 1.1†#

Body weight, plasma cholesterol and renin concentrations were measured after 28
days of infusions. Values are represented as mean ± SEM. * Ten mice were
initiated in the study, but 3 succumbed to aortic rupture, so data were derived from
7 surviving mice. † P<0.0001, compared to vehicle within saline or AngII groups. #
P=0.005, compared to saline infusion within vehicle or amlodipine groups.
doi: 10.1371/journal.pone.0081743.t001

Amlodipine Prevented Development of AngII-induced
Aneurysms in Both Abdominal and Ascending Aortic
Regions

Amlodipine Reduced Atherosclerosis in AngII-infused
Hypercholesterolemic Mice

Three of 10 mice infused with AngII died of aortic rupture
within 10 days after initiating AngII infusion, while no aortic
ruptures occurred in the other 3 groups as shown in Figure 2.
To determine effects of amlodipine on development of AAAs,
maximal diameters of suprarenal aortas were measured ex
vivo. Amlodipine had no effect on suprarenal aortic width in
saline-infused mice. As described previously, infusion of AngII
led to profound increases of maximal aortic width (saline +
vehicle versus AngII + vehicle: 0.86 ± 0.02 versus 1.72 ± 0.26
mm; P=0.0006). Amlodipine administration significantly
attenuated AngII-induced abdominal aortic dilation (1.02 ± 0.14
mm; P=0.003; Figure 3). Aortas from AngII-infused mice
administered with amlodipine were grossly normal as
demonstrated by histological analysis (Figure 4). To determine

PLOS ONE | www.plosone.org

Atherosclerotic lesion size was only minor in mice infused
with saline + vehicle and saline + amlodipine after 5 weeks of
feeding the saturated fat-enriched diet. Consistent with
previous studies [9,39], mice infused with AngII had
significantly increased lesion area in the thoracic aorta (saline +
vehicle versus AngII + vehicle: 0.22 ± 0.18 % versus 5.76 ±
2.29 %; P=0.02; Figure 6). Co-infusion of amlodipine reduced
atherosclerosis in AngII-infused mice (0.27 ± 0.14 %; P=0.05).

Discussion
AngII infusion simultaneously induces aneurysms in the
suprarenal and ascending regions of the aorta and augments
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Figure 3. Amlodipine ablated AngII-induced abdominal aortic aneurysms. Ex vivo suprarenal aortic diameter was measured
after termination. Circles and triangles are individual measurements, diamonds means of the groups, and error bars SEMs.
Representative images of aortas are shown below the graph. Statistical analyses were performed using nonparametric KruskalWallis test. * denotes P=0.0006 for comparison between AngII + vehicle and saline + vehicle, and # denotes P=0.003 for comparison
between AngII + amlodipine and AngII + vehicle groups.
doi: 10.1371/journal.pone.0081743.g003

atherosclerosis in hypercholesterolemic mice, as demonstrated
in the present and previous studies [9,12,14,40]. Despite
markedly different vascular pathologies promoted by chronic
AngII infusion, the present study provides evidence that
continuous infusion of a dihydropyridine calcium channel
blocker, amlodipine, has pronounced effects on inhibition of
these diverse pathologies that developed in mice rendered
hypercholesterolemia by deletion of LDL receptor and feeding
a diet that has a high saturated fat content (42% by calories),
compared to normal laboratory diet (18% fat by calories).
Amlodipine has commonly been administrated by gavage,
mixed with diet, or dissolved in drinking water [41-46]. In the
present study, amlodipine was given using osmotic minipumps,
as used in a previous study [47]. This approach was used to
provide stable calcium channel blockade throughout the 28
days of AngII infusion. In addition to providing a mode of
constant drug delivery, we also measured plasma
concentrations of this drug in mouse plasma. The detected
concentrations (mean concentration of saline + amlodipine and
AngII + amlodipine: 29.3 ± 1.7 ng/ml) are above the reported
EC50 of amlodipine [48,49]. By comparison to humans, a
single dose of 10 mg amlodipine to healthy male volunteers
resulted in plasma concentrations of 5.9 ± 1.2 ng/ml. Repeated
daily dosing led to mean plasma concentrations of 14.5 ± 5.8
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ng/ml with peaks and troughs of 18.1 ± 7.1 and 11.8 ± 5.3
ng/ml, respectively [50,51]. Therefore, plasma concentrations
of amlodipine achieved in this mouse study were in a similar
range to those achieved in humans.
Previous studies have demonstrated that increased systolic
blood pressure observed during AngII infusion is not the
determinant of aortic aneurysmal formation or atherosclerosis
augmentation [14,40,52,53]. In agreement with these previous
reports, the present study also found that amlodipine reduced
all vascular pathologies without resulting in any measurable
change in systolic blood pressure. This result extends the
findings by Kanematsu et al. [54], who reported that amlodipine
reduced both systolic blood pressure and aortic aneurysmal
formation in normocholesterolemic mice.
We also found that amlodipine administration increased
plasma renin concentrations. Previous studies suggest that
amlodipine has biphasic effects on plasma renin activity in
rodents, with reductions at low doses and stimulation of renin
at higher doses [55]. The basis for amlodipine exerting these
effects on plasma renin concentrations has not been defined.
In our experience, plasma renin concentrations in mice are
inversely related to plasma concentrations of AngII [24,56,57],
as also demonstrated in the present study by pronounced
reductions in plasma renin concentrations in AngII-infused
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Figure 4. Amlodipine preserved normal aortic structure in the suprarenal and ascending regions. Tissue sections from
AngII-infused mice also infused with amlodipine were immunostained with alpha actin and CD68 to detect smooth muscle cells and
macrophages, respectively. Positive reactivity is show by intense red color. Verhoeff’s hematoxylin staining was performed to
facilitate visualization of elastin.
doi: 10.1371/journal.pone.0081743.g004

mice. Therefore, the observed elevations in plasma renin
concentration by amlodipine suggest a reduction in
endogenous production of AngII. This may have contributed to
the ability of amlodipine to reduce vascular pathologies.
Although both abdominal and ascending aortic aneurysms
are defined by pronounced aortic luminal expansion,
pathologies in these two locations are distinct [12,22,58-60]. In
AngII infused mice, abdominal aortic aneurysms appear to be
initiated by rapid medial macrophage accumulation co-localized
with focal elastin fragmentation, and these changes are
followed by rapid luminal expansion and marked leukocyte
infiltration in the adventitia [61,62]. In contrast, during the
initiation of AngII-induced ascending aortic aneurysms, one of
the earliest pathological changes is hemorrhage restricted to
the outer medial layers, and subsequent concentric medial
changes and luminal dilation, while leukocyte infiltration is not
as pronounced as in abdominal aortic aneurysms [60]. In spite
of significant differences of these two aortic aneurysms, the
present study demonstrated that amlodipine reduced aortic
expansion in both abdominal and ascending regions. In
agreement with our findings, a recent study reported that
amlodipine profoundly reduced incidence of abdominal and
thoracic aortic aneurysms in normocholesterolemic mice coadministered either AngII or deoxycorticosterone acetate-salt
with a lysyl oxidase inhibitor, beta-aminopropionitrile [54]. This

PLOS ONE | www.plosone.org

model creates profound dilation of a translucent aorta from the
middle of the ascending region to aortic orifice of the
subclavian arterial branch. Therefore, this pathology differs
from that formed during AngII infusion in which dilation is
restricted to the full length of the ascending aorta and the
media is thickened and opaque [12]. Despite differences in
gross appearance, amlodipine markedly decreased thoracic
aortic pathologies in both animal models. Currently, information
from humans with ascending aortic aneurysms is limited to a
small study inferring benefits in young patients with Marfan’s
syndrome who were administered a non-dihydropyridine
calcium channel blocker, verapamil [63].
Calcium channel blockade has also been studied in a rat
model of abdominal aortic aneurysms induced by intra-aortic
infusion of elastase. Two different members of the
dihydropyridine class of calcium channel blockers, azelnidipine
and nifedipine, reduced AAAs formed in this model [64,65]. In
contrast to these reports and what was found in the present
study, a retrospective investigation reported that calcium
channel blockade was associated with the presence of
abdominal aortic aneurysms. However, administration of
calcium channel blockers did not affect aortic dilation rate. The
authors acknowledged potential compounding factors in this
retrospective analysis and noted the need for prospective
studies [25]. Currently, two prospective studies are evaluating
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Figure 5. Amlodipine attenuated AngII-induced ascending aortic aneurysms. Ascending aortic areas were measured using
an en face method. Circles and triangles are individual measurements, diamonds are means of groups, and error bars are SEMs.
Representative images of aortas are shown below the graph. Statistical analyses were performed using nonparametric KruskalWallis test. * denotes P=0.001 for comparison between AngII + vehicle and saline + vehicle groups, and # denotes P=0.03 for
comparison between AngII + amlodipine and AngII + vehicle groups.
doi: 10.1371/journal.pone.0081743.g005

effects of amlodipine on growth of AAAs in humans
(NCT01425242 and NC01118520). Completion of these
studies will provide insight into the validity of translating results
from AngII-induced AAAs in mice to humans.
In contrast to the limited information on aortic aneurysms,
there have been many experimental and human studies to
determine effects of multiple calcium channel blockers on
atherosclerosis [66]. Several of these studies have investigated
effects of amlodipine in mouse atherosclerosis models with
either apoE deletion or mutation. These reports provided a
range of results with amlodipine reducing atherosclerotic lesion
size [41,42,46,67-69] or having no effect [43-45,70]. In the
present study, we used saturated fat-fed LDL receptor -/- mice
infused with AngII, and found that amlodipine decreased
atherosclerosis. The conflicting findings in the literature may be
partially explained by different doses of amlodipine used and
mode of drug delivery; however, potential mechanisms of the
conflicting findings remain to be unraveled.
The overt differences in the appearance of AngII-induced
abdominal aortic aneurysms, ascending aortic aneurysms, and

PLOS ONE | www.plosone.org

atherosclerosis imply that the octapeptide is stimulating several
mechanisms to produce these diverse pathologies. Therefore,
the profound effects of amlodipine on all these pathologies also
imply that the drug is potentially interfering with many
mechanisms. Amlodipine has been demonstrated to influence
many processes that have been invoked in AngII-induced
vascular pathologies include reductions in oxidant stress [41],
matrix metalloproteinases [71], nitric oxide synthesis [72], and
leukocyte migration [47]. However, the contribution of each of
these mechanisms to reducing AngII-induced vascular
pathologies remains to be determined.
In conclusion, administration of amlodipine was studied in a
mouse model that simultaneous developments aortic
aneurysms and atherosclerosis. Although several studies have
observed disparities in response to different AngII-induced
vascular pathologies, this study demonstrated that continuous
infusion of amlodipine, at a dose that achieved therapeutically
relevant plasma concentrations, markedly reduced all these
pathologies.
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Figure 6. Amlodipine reduced AngII-induced atherosclerosis. Percent atherosclerotic lesion area of thoracic aortas were
measured by an en face method. Circles and triangles are individual measurements, diamonds are means of the groups, and error
bars are SEMs. Statistical analyses were performed using nonparametric Kruskal-Wallis test. * denotes P=0.02 for comparison
between AngII + vehicle and saline + vehicle groups, and # denotes P=0.05 for comparison between AngII + amlodipine and AngII +
vehicle groups.
doi: 10.1371/journal.pone.0081743.g006
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